Bausch & Lomb's Crystalens approved by FDA
This article was originally published in Clinica
Bausch & Lomb's Crystalens HD accommodating intraocular lens (IOL) has received premarket approval (PMA) from the US FDA. It is the fourth-generation Crystalens product – the first gained FDA clearance in November 2003. The Rochester, New York company hopes to launch the lens in Europe, Asia and Canada in early 2009. Bausch & Lomb agreed to buy Crystalens' developer eyeonics in January 2008 – before this it only offered monofocal IOLs. Crystalens is designed to correct presbyopia, the eye's inability to accommodate and focus on close objects, using the eye muscles to push the IOL back and forth. Crystalens HD has an enhanced optic which increases depth of focus to improve near vision without compromising intermediate or distance vision, Bausch & Lomb said.